Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: Analysis of their prognostic significance in squamous cell carcinoma of the head and neck

Anticancer Research

Volumn 20, Issue 5 C, 2000, Pages 3975-3981

  Strojan, P ^a   Budihna, M ^a   Smid, L ^a   Vrhovec, I ^a   Skrk, J ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Cathepsin D; Head and neck carcinoma; Plasminogen activator inhibitor type 1; Prognosis; Squamous cell carcinoma; Urokinase type plasminogen activator

Indexed keywords

CATHEPSIN D; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CORRELATION FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SQUAMOUS CELL CARCINOMA; TISSUE LEVEL;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; CATHEPSIN D; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOIMMUNOASSAY; RECURRENCE; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034532067     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer
2. Tumour-associated proteases
3. The urokinase-type plasminogen activator, its inhibitors and its receptor - The new prognostic factors in solid cancers
4. Cathepsins and their endogenous inhibitors in clinical oncology
5. Cathepsin D concentration in primary laryngeal cancer: Correlation with clinicopathological parameters, EGFR status and patients
6. Cervical lymph node status and survival in laryngeal carcinoma: Prognostic factors
7. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma
8. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients
9. Cathepsin D in tissue and serum of patients with squamous cell carcinoma of the head and neck
10. A rapid sensitive method for the quantification of microgram quantities of protein utilising the principle of protein-dye binding
11. Nonparametric estimation from incomplete observation
12. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
13. Regulation of cell adhesion by PAI-1
14. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularisation
15. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor type 1
16. Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues
17. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop
18. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts
19. Prognostic value of cathepsins B, D and stefins A and B in laryngeal carcinoma